King Pharmaceuticals News

Forbes' Matthew Herper notes that the CEO of Fougera, which Novartis is buying for $1.525B , is Brian Markison, who was CEO of King Pharmaceuticals when it was sold to Pfizer for $3.6B in 2010.

What's eye-catching here is not the price of the deal, but the identity of the chief executive: Brian A. Markison, who was chief executive of King Pharmaceuticals, the specialty drug firm that was sold to Pfizer for $3.6 billion in 2010.

New Jersey-based specialty pharmaceuticals company Alpharma Inc.'s board of directors took a leaf out of biotechnology firm ImClone Systems and formally rejected King Pharmaceuticals' hostile takeover bid of $37.00 a share on Friday, asserting that the offer was too low.

Pfizer Inc, the world's largest drug maker, today disclosed plans to acquire King Pharmaceuticals Inc, a diversified specialty pharmaceutical discovery and clinical development company, for $3.6 billion in cash, to strengthen its position in the pain relief market.

D.N. Chadha arrived in the U.S. in 1970 with only one suitcase and $600 in his pocket.